Chrysotoxine
CAS No. : 156951-82-5
| Size | Price | Stock |
|---|---|---|
| 1mg | $170 | In-stock |
| 5 mg | Get quote | |
| 10 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-123298 |
| M.Wt: | 318.36 |
| Formula: | C18H22O5 |
| Purity: | >98 % |
| Solubility: | DMSO : 6.37 mg/mL (ultrasonic;warming) |
Chrysotoxine is a dual inhibitor of Src/Akt. Chrysotoxine suppresses cancer stem cells (CSCs) phenotypes by down-regulating Src/Akt signaling. Chrysotoxine reduces cell viability and increases apoptosis level in H460 and H23 cells instead of non-tumor cell lines. Chrysotoxine shows rapid excretion and low bioavailability in rats. Chrysotoxine is used in cancer research[1][2].
In Vitro:Chrysotoxine (50 nM, 24 h) reduces cell viability and increases apoptosis level in H460 and H23 cells[1].
Chrysotoxine (5-20 nM, 72 h) suppresses the CSC populations in H460 and H23 cells[1].
Chrysotoxine (0-20 nM, overnight) decreases the stemness of H460 and H23 cells by suppressing
the Src-Akt activating mechanism[1].
In Vivo:Chrysotoxine (25 mg/kg for i.v; 100 mg/kg for p.o;once) rapidly excreted and has low bioavailability in Sprague-Dawley rats model[2].
Pharmacokinetic parameters of Chrysotoxine in Sprague-Dawley rats[2]
| Parameters | Intravenous | Oral |
| AUC0–t (μg h/L) | 1257.6 ± 570.7 | 172.8 ± 118.9 |
| AUC0–∞ (μg h/L) | 1270.1 ± 560.6 | 202.5 ± 123.8 |
| MRT0–t (μg h/L) | 0.467 ± 0.056 | 1.2 ± 0.46 | MRT0–∞ (μg h/L) | 0.59 ± 0.21 | 2.4 ± 1.8 |
| t1/2Z ( h) | 1.4 ± 0.76 | 1.7 ± 1.1 |
| Tmax ( h) | / | 0.098 ± 0.040 |
| CLZ /F (L/h/kg) | 22.9 ± 11.2 | 668.7 ± 396.9 |
| VZ /F (L/kg) | 55.3 ± 54.1 | 1443.2 ± 943.0 |
| Cmax (μg/L) | 4961.2 ± 3254.8 | 408.8 ± 160.5 |
| F (%) | / | 3.4 ± 2.4 |